Future of Colorectal Cancer Surgery

NCT ID: NCT04220242

Last Updated: 2020-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-12-30

Study Completion Date

2023-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer is the third most common cancer in the UK and Ireland, it is the second commonest cancer in both men and women. Very often the diagnosis is made by either endoscopy/colonoscopy and the surgical treatment is carried out by a minimally invasive approach ("Keyhole"surgery). Tissue samples gathered by either approach are sent to the pathologist to confirm the nature of their content. At present this takes some time (days) and so the information cannot guide the procedure being done or indeed any other investigations or processes that need implementation as soon as possible until the pathology process is completed. Fluorescence guided surgery uses an approved dye along with approved cameras to add more information regarding tissue characteristics then is available by normal viewing alone. It has already been shown to be associated with an improvement in safety related to healing after colorectal surgery and the investigators are sooning in a randomised trial examining this in rectal cancer to prove it. Whether or not this trial proves this or not, the ability to better understand tissue health during investigation/operation needs further examination and development. In this study, the investigators will examine the role of computer vision and machine learning in determining the nature of the tissue being seen in real-time additive to the surgeons' own opinion and experience. This is needed because the dynamic phases of fluorescence inflow into any tissue is difficult to interpret most especially when it relates to microvasculature as is present within a cancer site or deposit. By this means the investigators hope to better understand the dynamic perfusion in and out of tissue whether normal or abnormal and define signatures that can speed up and/or help inform the surgeon regarding the actual nature of the tissue being seen. The investigators will compare the data being generated with that already being captured with regard to standard pathology and radiology and other laboratory measures of clinical course. Tissue resected from a patient will also be examined in the laboratory under near-infrared microscopy and analysed for fluorescence intensity to understand where exactly and how much of the dye accumulates in specific regions of tissue. There are no new operations in this study and no new interventions are being made on the basis of the information being gathered- it's a comparative study to see how this added information can add value to interventionalists during surgery. There are four collaborating groups involved in this research consortium, two are commercial partners as they add value in both this advanced field of analytics and in the ensuring a clinical business case is included so that findings of this work can be useful for patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a combined retrospective and prospective, unblinded, non-CTIMP, multicentre, observational study to develop and determine methods of applying CV and AI with IFA in surgery for clinical benefit in surgery. Surgery can be performed via a minimally invasive fashion whether by an endoscopic or a laparoscopic or robotic technique (the latter depending on surgeon's preference) as part of either a diagnostic or therapeutic intervention in the standard way based on the patients' clinical need. Either before or during the procedure, a visual contrast agent will be administered by peripheral cannula and the area of interest examined by use of a near-infrared scope to determine presence, persistence and inflow/outflow pathways of the dye. The video image will be subjected to further analysis by computer vision and data analytics for the purposes of elucidating specific patterns enabling machine learning to build algorithms for flow characterisation informed by biophysics and pseudo-anonymised clinical data. The developmental algorithms will be additionally informed by mechanistic work quantifying and localising the fluorescence agent within and around sites of abnormal disease by digital fluorescence scanning and near-infrared microscopy as well as deep characterisation of dye clearance dynamics and local tissue metabolites (particularly acidosis). In addition, some tissue from the resected specimens provided in the course of diagnostic investigation or cancer surgery will be used to develop organoids for the purpose of examining in vitro tumour uptake and distribution of fluorescence agents.

In all 250 patients will be studied over the three-year period, comprising 100 patients undergoing anastomotic construction and 100 undergoing cancer diagnostics/resection. Some patients can be included in both groups). Following development (potentially earlier then above), prospective validation will be performed on approximately 25 patients in each group. The follow-up period ends 30 days after recruitment. The trial will not be blinded to participants, medical staff, or clinical trial staff. The contrast agents used are clinically approved (including indocyanine green) for such use within this study. While the validation component of this work will be performed prospectively, the initial model development will include some data from patients retrospectively who have already undergone similar evaluation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Video recordings with analysis thereafter applied

Recordings of surgical assessments in order to develop a model for Artificial Intelligence analysis

Intervention Type OTHER

Examination of microsections of tissue excised for the purposes of cancer resection

Microscopic examination including by near-infrared examination of some of the tissue excised for the purposes of cancer resection to examine cellular mechanisms of fluorescence uptake and distribution

Intervention Type OTHER

Cancer organoid development and testing

Some tissue will be taken from the specimens excised for the purposes of the cancer operation to develop experimental models of cancer tissue to allow examination of mechanisms of uptake and distribution of the fluorophores in cancer

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Participant is willing and able to give informed consent for participation in the study.

* Male or Female, aged 18 years or above.
* Clinical features suspicious of or diagnosed with colorectal neoplasia or other colorectal disease requiring segmental resection with anastomosis.
* No prior allergy to indocyanine green or iodine.
* If female and of potential child-bearing age, have a negative pregnancy test at time of study participation.
* Participant has clinically acceptable laboratory results, including liver function tests.
* In the Investigator's opinion, is able and willing to comply with all study requirements.
* Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study.

Exclusion Criteria

* • Female participant who is pregnant, lactating or planning pregnancy during the course of the study.

* Significant renal or hepatic impairment.
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Royal College of Surgeons, Ireland

OTHER

Sponsor Role collaborator

IBM Research In Ireland

UNKNOWN

Sponsor Role collaborator

Mater Misericordiae University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ronan Cahill

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ronan Cahill

Role: PRINCIPAL_INVESTIGATOR

University College Dublin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mater Misericordiae University Hospital

Dublin, Other (Non U.s.), Ireland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Ireland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ronan Cahill

Role: CONTACT

+35317164597

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ronan Cahill

Role: primary

0035317164597

Debbie Killeen

Role: backup

00353 1 7164597

References

Explore related publications, articles, or registry entries linked to this study.

Hardy NP, MacAonghusa P, Dalli J, Gallagher G, Epperlein JP, Shields C, Mulsow J, Rogers AC, Brannigan AE, Conneely JB, Neary PM, Cahill RA. Clinical application of machine learning and computer vision to indocyanine green quantification for dynamic intraoperative tissue characterisation: how to do it. Surg Endosc. 2023 Aug;37(8):6361-6370. doi: 10.1007/s00464-023-09963-2. Epub 2023 Mar 9.

Reference Type DERIVED
PMID: 36894810 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DT 2018 0240

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.